Drug shows promise in slowing cognitive decline, opening market for early dementia treatment

Roflumilast may help patients with mild cognitive impairment preserve brain function, according to new research. The finding could reshape treatment strategy for early dementia stages and create a significant commercial opportunity if cost-effectiveness data supports wider adoption.

Originaltitel: The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost-effectiveness of roflumilast